中加医疗创新混合发起式清盘 成立3年亏损2成

Core Viewpoint - The China-Canada Medical Innovation Mixed Fund has triggered termination conditions as its net asset value fell below 200 million RMB, leading to the initiation of the fund's liquidation process without the need for a shareholder meeting [2]. Fund Establishment and Termination - The China-Canada Medical Innovation Mixed Fund was officially established on November 30, 2022, after being registered [1]. - According to the fund contract, if the net asset value is below 200 million RMB three years after the contract's effective date, the fund will automatically terminate [2]. - The effective date of the fund contract is November 30, 2022, and the termination condition will be assessed on November 30, 2025 [2]. Fund Performance - As of the last disclosed net value date on December 1, 2025, the cumulative net value for Class A and Class C shares were 0.8135 RMB and 0.7996 RMB, respectively, with cumulative returns of -18.63% and -20.02% [2]. - The fund's performance in the current year shows a growth of 8.22% for Class A and 7.64% for Class C, while the one-year performance remains negative [4][5]. - The average return for similar funds is significantly higher at 33.12%, indicating underperformance relative to peers [4][5].